The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Determination Of The Efficacy And Resistance Profile Of A Long Acting Neuraminidase Inhibitor Against Several Avian Infl
Funder
National Health and Medical Research Council
Funding Amount
$91,350.00
Summary
Recent events have again highlighted influenza�s potential to cause a worldwide pandemic or be used as an agent of biowarfare. As of August 2005, the highly pathogenic Avian Flu sweeping through Asia has infected 112 people, killing 57. Over 150 million chickens have been slaughtered in an attempt to stop its spread, but with infection documented in migratory birds, containment may be difficult if not impossible. Experts believe that it is only a matter of time before the Avian Flu virus is capa ....Recent events have again highlighted influenza�s potential to cause a worldwide pandemic or be used as an agent of biowarfare. As of August 2005, the highly pathogenic Avian Flu sweeping through Asia has infected 112 people, killing 57. Over 150 million chickens have been slaughtered in an attempt to stop its spread, but with infection documented in migratory birds, containment may be difficult if not impossible. Experts believe that it is only a matter of time before the Avian Flu virus is capable of human to human transmission which could result in the deaths of hundreds of thousands of people worldwide. Should a pandemic arise, either through purposely-engineered or natural processes such as avian influenza, effective vaccines are unlikely to be available for at least 3-6 months. In such an event, treatment of infection and prevention of spread through post-exposure prophylaxis would be optimal, while pre-exposure prophylaxis would be most suited to key personnel such as army, medical and emergency-response staff. Biota is a world leading antiviral drug discovery company based in Melbourne, Australia with key expertise in viral respiratory diseases, particularly influenza. Biota developed the first in class neuraminidase inhibitors (NAI) drug, zanamivir (Relenza) and through a partnership with Glaxo Smith Kline (GSK) brought it to market. Biota also developed the FluOIA� for the rapid detection of Influenza A and B. Work has been underway at Biota for some time to develop a new generation of influenza drugs designed to be more active and longer acting than the first generation products. These long acting neuraminidase inhibitors (LANI) have the benefit of less frequent administration and a lower treatment dose making them an ideal choice for stockpiling. The proposed project aims to test the antiviral activity of LANI compound against the H5N1 influenza. The results of which could assist in a decision to fast track the clinical development of the compound with the aim of adding to the national stock pile of antivirals, thus helping Australia to prevent, prepare for and respond to a potential avian influenza-induced pandemic.Read moreRead less